Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications

Jeffrey Betcher, Elizabeth Dow, Nandita D Khera

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Apr 16 2016

Fingerprint

Pharmaceutical Economics
Drug Therapy
Health Personnel
Patient Advocacy
Safety
Hematologic Neoplasms
Biological Products
Delivery of Health Care

Keywords

  • Medication adherence
  • Oral anticancer drugs
  • Oral cancer therapy
  • Oral chemotherapy
  • Oral parity
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{5e51f2388dac4b68b29f904eeb7019c9,
title = "Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications",
abstract = "Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.",
keywords = "Medication adherence, Oral anticancer drugs, Oral cancer therapy, Oral chemotherapy, Oral parity, Pharmacoeconomics",
author = "Jeffrey Betcher and Elizabeth Dow and Khera, {Nandita D}",
year = "2016",
month = "4",
day = "16",
doi = "10.1007/s11899-016-0325-2",
language = "English (US)",
pages = "1--7",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications

AU - Betcher, Jeffrey

AU - Dow, Elizabeth

AU - Khera, Nandita D

PY - 2016/4/16

Y1 - 2016/4/16

N2 - Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.

AB - Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.

KW - Medication adherence

KW - Oral anticancer drugs

KW - Oral cancer therapy

KW - Oral chemotherapy

KW - Oral parity

KW - Pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84963764079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963764079&partnerID=8YFLogxK

U2 - 10.1007/s11899-016-0325-2

DO - 10.1007/s11899-016-0325-2

M3 - Article

C2 - 27086140

AN - SCOPUS:84963764079

SP - 1

EP - 7

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -